Abstract
Chronic Achilles tendinopathy is a debilitating condition that significantly affects mobility and quality of life. Platelet-rich plasma (PRP) therapy has been proposed as a treatment option, leveraging growth factors to promote tendon healing, but its effectiveness remains unclear. This review aimed to evaluate the effectiveness of PRP in reducing pain, improving function, and facilitating recovery in chronic Achilles tendinopathy. A total of 13 studies involving 697 patients were analyzed. Key outcomes included pain reduction (measured by visual analog scale {VAS}), functional improvement (Victorian Institute of Sports Assessment-Achilles {VISA-A}), return to activity, and patient satisfaction. Study variability was analyzed using heterogeneity measures. PRP demonstrated significant pain reduction (pooled mean VAS: 71.24, 95% CI: 53.06-89.42). Functional improvement was observed (VISA-A scores: 35.10-86.80). On average, 85% of patients returned to activity (95% CI: 65-98%) and 72% reported satisfaction (95% CI: 51-88%). High heterogeneity (I²=97%) was noted, likely due to variability in PRP preparation and treatment protocols. PRP offers promise as a treatment for chronic Achilles tendinopathy, with evidence of pain relief and functional improvement. However, variability in outcomes emphasizes the need for standardized approaches to its use and further research to better define its role in clinical practice.